Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.

Bruinsmann FA, Richter Vaz G, de Cristo Soares Alves A, Aguirre T, Raffin Pohlmann A, Stanisçuaski Guterres S, Sonvico F.

Molecules. 2019 Nov 26;24(23). pii: E4312. doi: 10.3390/molecules24234312. Review.

2.

Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

van Woensel M, Wauthoz N, Rosière R, Amighi K, Mathieu V, Lefranc F, van Gool SW, de Vleeschouwer S.

Cancers (Basel). 2013 Aug 14;5(3):1020-48. doi: 10.3390/cancers5031020.

3.

[Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].

Kanazawa T.

Yakugaku Zasshi. 2018;138(4):443-450. doi: 10.1248/yakushi.17-00179. Review. Japanese.

4.

Lipid Nanoparticles for Nasal/Intranasal Drug Delivery.

Cunha S, Amaral MH, Lobo JMS, Silva AC.

Crit Rev Ther Drug Carrier Syst. 2017;34(3):257-282. doi: 10.1615/CritRevTherDrugCarrierSyst.2017018693. Review.

PMID:
28845761
5.

Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.

Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A.

J Control Release. 2018 Jul 10;281:139-177. doi: 10.1016/j.jconrel.2018.05.011. Epub 2018 May 24. Review.

PMID:
29772289
6.

Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.

Arcella A, Palchetti S, Digiacomo L, Pozzi D, Capriotti AL, Frati L, Oliva MA, Tsaouli G, Rota R, Screpanti I, Mahmoudi M, Caracciolo G.

ACS Chem Neurosci. 2018 Dec 19;9(12):3166-3174. doi: 10.1021/acschemneuro.8b00339. Epub 2018 Jul 31.

PMID:
30015470
7.

Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models.

Wang W, Swenson S, Cho HY, Hofman FM, Schönthal AH, Chen TC.

J Neurosurg. 2019 Mar 15:1-9. doi: 10.3171/2018.11.JNS181161. [Epub ahead of print]

PMID:
30875688
8.

Drug delivery approaches for the treatment of glioblastoma multiforme.

Fakhoury M.

Artif Cells Nanomed Biotechnol. 2016 Sep;44(6):1365-73. doi: 10.3109/21691401.2015.1052467. Epub 2015 Jun 5. Review.

PMID:
26046399
9.

Insights into direct nose to brain delivery: current status and future perspective.

Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J.

Drug Deliv. 2014 Mar;21(2):75-86. doi: 10.3109/10717544.2013.838713. Epub 2013 Oct 9. Review.

PMID:
24102636
10.

Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE.

Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6. Review.

PMID:
25791797
11.

Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics.

Kumar H, Mishra G, Sharma AK, Gothwal A, Kesharwani P, Gupta U.

Pharm Nanotechnol. 2017;5(3):203-214. doi: 10.2174/2211738505666170515113936. Review.

PMID:
28521670
12.
13.

Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma.

Harder BG, Blomquist MR, Wang J, Kim AJ, Woodworth GF, Winkles JA, Loftus JC, Tran NL.

Front Oncol. 2018 Oct 23;8:462. doi: 10.3389/fonc.2018.00462. eCollection 2018. Review.

14.

Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.

Bastiancich C, Danhier P, Préat V, Danhier F.

J Control Release. 2016 Dec 10;243:29-42. doi: 10.1016/j.jconrel.2016.09.034. Epub 2016 Sep 28. Review.

PMID:
27693428
15.

The potential of polymeric micelles in the context of glioblastoma therapy.

Morshed RA, Cheng Y, Auffinger B, Wegscheid ML, Lesniak MS.

Front Pharmacol. 2013 Dec 30;4:157. doi: 10.3389/fphar.2013.00157. Review.

16.

Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.

Agarwal S, Muniyandi P, Maekawa T, Kumar DS.

Int J Pharm. 2018 Nov 15;551(1-2):339-361. doi: 10.1016/j.ijpharm.2018.09.033. Epub 2018 Sep 17. Review.

PMID:
30236647
17.

RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Lozada-Delgado EL, Grafals-Ruiz N, Vivas-Mejía PE.

Life Sci. 2017 Nov 1;188:26-36. doi: 10.1016/j.lfs.2017.08.027. Epub 2017 Aug 31. Review.

18.

The blood-brain barrier and nasal drug delivery to the central nervous system.

Miyake MM, Bleier BS.

Am J Rhinol Allergy. 2015 Mar-Apr;29(2):124-7. doi: 10.2500/ajra.2015.29.4149. Review.

PMID:
25785753
19.

Progress in brain targeting drug delivery system by nasal route.

Khan AR, Liu M, Khan MW, Zhai G.

J Control Release. 2017 Dec 28;268:364-389. doi: 10.1016/j.jconrel.2017.09.001. Epub 2017 Sep 6. Review.

PMID:
28887135
20.

Supplemental Content

Support Center